Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | Should we transplant or not in frontline therapy for MCL?

Tycel Phillips • 3 Jun 2019
ASCO 2019
Lymphoma Mantle Cell Lymphoma

Tycel Phillips, MD, of the University of Michigan, Ann Arbor, MI, discusses if we should transplant or not in frontline therapy for mantle cell lymphoma (MCL) at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Tycel Phillips

0:51
An update from ASH 2023: advancements in NHL treatment
Tycel Phillips • 10 Dec 2023
1:54
A retrospective analysis of real-world data from patients treated for R/R follicular lymphoma
Tycel Phillips • 10 Dec 2023
1:55
Optimal sequencing of CAR-T and bispecifics in NHL
Tycel Phillips • 10 Dec 2023
1:17
GLOBRYTE: investigating glofitamab monotherapy in patients with R/R MCL
Tycel Phillips • 10 Dec 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals